1. In this randomized, double-blind, placebo-controlled trial, the use of once-weekly subcutaneous TG103 resulted in significant weight reduction at 12 weeks at all dosages. 2. It was deemed to be safe and effective, with pharmacokinetic findings in keeping with the weekly dose regimen recommended in preclinical studies. Evidence Rating Level: 1 (Excellent) Obesity, caused by